Jubilant Life Sciences Ltd which is an integrated global Pharmaceutical and Life Sciences Company, has announced that it has bagged Abbreviated New Drug Application (ANDA) final approval for Rosuvastatin Calcium Tablets, 5 mg, 10 mg, 20 mg as well as 40 mg, the generic version of Crestor of IPR Pharmaceuticals, which is used for the treatment of hyperlipidemia or mixed dyslipidemia.
The Company has received 7 approvals from the USFDA during the year. As on 30th September, 2016, Jubilant Life Sciences had a total of 72 ANDAs for Oral Solids filed in the US, of which 47 have been approved.
Jubilant share price is currently trading at Rs 694.2, up by Rs 7.25 or 1.06 per cent from its previous closing of Rs 686.95 on the Bombay Stock Exchange.
Jubilant share price opened at Rs 688 and has touched a high and low of Rs 705.05 and Rs 671.05 respectively. So far 1069447(NSE and BSE) shares were traded on the counter. The current market cap of the company is Rs 10943.11 crores.
The BSE group 'A' stock has a face value Re 1 and has touched a 52 week high of Rs 700.9 on 19th October 2016 and a 52 week low of Rs 272.5 on 20th January 2016. Last one week high and low of the share stood at Rs 698 and Rs 637.5 respectively.
The promoters holding in the company stood at 54.02 per cent while Institutions and Non-Institutions held 26.26 per cent and 17.34 per cent respectively. Jubilant is a multibagger, as per Dynamic Levels Researchers.
Jubilant Life Sciences Ltd is an integrated global pharmaceutical as well as life sciences company engaged in manufacturing and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products, Advance Intermediates, Fine Ingredients, Crop Science Ingredients, and Life Science Chemicals along with Nutritional Products. It also provides services in Contract Manufacturing of Sterile Injectables and Drug Discovery Solutions. The firm’s strength lies in its unique offerings of Pharmaceutical and Life Sciences products and services.
Source: www.dynamiclevels.com
No comments:
Post a Comment